课题基金 / 基金详情

Studies of concentric sclerosis (Balo) in the Philippines

Studies of concentric sclerosis (Balo) in the Philippines
菲律宾的同心圆硬化症(Balo)研究
批准号:
05044194
负责人:
TABIRA Takeshi
金额:
$4.16万
依托单位国家:
日本
项目类别:
Grant-in-Aid for international Scientific Research
财政年份:
1993
资助国家:
日本
项目状态:
已结题
起止时间:
1993 至 1994

项目摘要

项目成果

TABIRA Takeshi的其他基金

相似基金

相关文献

中文摘要
翻译
我们调查了菲律宾Balo's同心硬化患者。2年内共收集病例34例。平均发病年龄26.5岁,男女比例为1:1 .6。患者出现急性起病行为改变、沉默、四肢或偏瘫伴双重失禁,并对类固醇有反应。脑脊液除白细胞计数和IgG轻微升高外,无显著性变化,MRI显示脑白质多灶性或弥漫性融合性病变。除1例复发外,临床病程为单相。我们发现了2例家族性病例。HLA-DRB1*1502在74%的Balo患者中被发现,显著高于对照组(36%)。此外,44%的Balo患者中发现DRB1*1502纯合子,显著高于MS(0%)和对照组(5.6%)。髓鞘碱性蛋白和蛋白脂质蛋白无明显免疫应答,病毒抗体无明显免疫应答。
英文摘要
We investigated the patients with Balo's concentric sclerosis in the Philippines. A total of 34 cases was collected in 2 years. Mean age of onset was 26.5 years and male to female ratio was 1 : 1.6. Patients developed acute onset of behavioral change, muteness, quadi- or hemiplegia with double incontinence, and responded to steroids. CSF was not remarkable except for slightly elevated white blood cell count and IgG,and MRI showed multifocal or diffuse confluent lesions in the cerebral white matter. The clinical course was monophasic except for one who showed one relapse. We found 2 familial cases. HLA-DRB1*1502 was found in 74% of Balo's patients, which was significantly higher than controls (36%) . Moreover, homozygote of DRB1*1502 was found in 44% of Balo's patients, which was significantly higher than MS (0%) and controls (5.6%) . No significant immune response to myelin basic protein and proteolipid protein was found, and none of virus antibodies were significant.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
田中 武: "同心円硬化症" 日本臨床. 52. 2971-2975 (1994)
Takeshi Tanaka:“同心硬化”日本临床杂志 52. 2971-2975 (1994)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Analysis of immune mechanisms of Alzheimer's disease and development of a novel treatment
Identification of aging-related factors that facilitate Alzheimer's disease
ミクログリアに発現しマクロファージに発現しない遺伝子の同定
Molecular cloning of IL-3 receptor-associated antigen
海外基金